Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berthier, M. L.
Right arrow Articles by Martín, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berthier, M. L.
Right arrow Articles by Martín, M. C.
Related Collections
Right arrow Aphasia
Right arrow All Cerebrovascular disease/Stroke
Right arrow Infarction
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
NEUROLOGY 2006;67:1687-1689
© 2006 American Academy of Neurology
Brief Communications

A randomized, placebo-controlled study of donepezil in poststroke aphasia

M. L. Berthier, MD, PhD, C. Green, PhD, C. Higueras, PhD, I. Fernández, PhD, J. Hinojosa, PhD and M. C. Martín, PhD

From Centro de Investigaciones Médico-Sanitarias (CIMES) (M.L.B., C.G., C.H., J.H.), University of Malaga School of Medicine; and Language Rehabilitation Center (CIMPER) (I.F., M.C.M.), Malaga, Spain.

Address correspondence and reprint requests to Dr Berthier, Centro de Investigaciones Médico-Sanitarias (CIMES), Universidad de Málaga, Campus Teatinos, 29071 Málaga, Spain; e-mail: mberthier{at}terra.es, mbt{at}uma.es

We studied 26 patients in a randomized, placebo-controlled, double-blind parallel trial to evaluate the efficacy and safety of donepezil in chronic poststroke aphasia. Donepezil (10 mg/day) improved aphasia severity at endpoint (week 16) relative to placebo (p = 0.037).

Disclosure: Dr. M.L. Berthier has received honoraria from Pfizer Spain, Eisai, Janssen-Cilag, Novartis, Lundbeck, and Merz in excess of $10,000. Dr. C. Green has received honoraria from Janssen-Cilag and Lundbeck. Pfizer Spain and Eisai supplied the active medication and placebo.

Received March 27, 2006.

Accepted in final form July 7, 2006.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.